Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated "Hold" by Wall Street Analysts

Key Points

• Analysts maintain a “Hold” consensus on Lantheus, with 10 hold ratings and four buys among 14 firms. The average 12-month price target is $108.11, while recent broker actions included downgrades and target-price reductions.
• Lantheus reported stronger-than-expected quarterly results, with EPS of $1.55 versus the $1.30 consensus estimate and revenue of $388.18 million versus $363.23 million expected. Revenue increased 2.7% year over year, and analysts expect approximately $4.50 in full-year EPS.
• The stock opened at $99.53, near its $100.89 50-day moving average, while institutional investors and hedge funds own 99.06% of outstanding shares.

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have received an average rating of "Hold" from the fourteen research firms that are covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $108.11.

A number of brokerages have recently issued reports on LNTH. TD Cowen downgraded Lantheus from a "buy" rating to a "hold" rating and reduced their price target for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Mizuho lowered their price objective on Lantheus from $120.00 to $115.00 and set an "outperform" rating for the company in a research report on Wednesday, July 29th. B. Riley Financial downgraded Lantheus from a "buy" rating to a "hold" rating in a research note on Monday, August 17th. William Blair set a $102.50 price target on Lantheus in a research note on Monday, August 3rd. Finally, Citizens Jmp reissued a "market outperform" rating and issued a $115.00 price target on shares of Lantheus in a report on Monday, June 29th.

Lantheus Stock Performance

LNTH stock opened at $99.53 on Thursday. Lantheus has a one year low of $49.67 and a one year high of $111.86. The firm has a market cap of $6.50 billion, a price-to-earnings ratio of 24.04 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The firm has a 50-day simple moving average of $100.89 and a two-hundred day simple moving average of $95.95.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The firm had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same quarter in the previous year, the firm earned $1.57 EPS. The company's quarterly revenue was up 2.7% compared to the same quarter last year. On average, equities analysts forecast that Lantheus will post 4.5 EPS for the current fiscal year.

Institutional Trading of Lantheus

A number of institutional investors have recently bought and sold shares of LNTH. Integrated Wealth Concepts LLC grew its position in Lantheus by 6.7% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 18,709 shares of the medical equipment provider's stock worth $2,076,000 after purchasing an additional 1,170 shares during the last quarter. Baird Financial Group Inc. raised its holdings in shares of Lantheus by 25.8% in the second quarter. Baird Financial Group Inc. now owns 29,356 shares of the medical equipment provider's stock worth $3,257,000 after buying an additional 6,013 shares during the last quarter. Carmignac Gestion lifted its stake in shares of Lantheus by 0.9% during the second quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider's stock worth $148,671,000 after buying an additional 12,100 shares during the period. Corient Private Wealth LP purchased a new stake in shares of Lantheus during the second quarter valued at $290,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Lantheus during the second quarter valued at $1,002,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc NASDAQ: LNTH is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company's portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.